Investor Presentaiton
Investor Presentation
First nine months of 2018
Slide 14
Key development milestones
Diabetes
Obesity
•
.
•
•
Successful completion of additional three phase 3a trials, PIONEER 5, 8 and 10, with oral semaglutide
Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins
Phase 1 trial initiated with OG2023SC investigating the safety, tolerability and pharmacokinetics
Two new drug applications have been submitted in Japan for XultophyⓇ and FiaspⓇ
Hypopen-1513 discontinued
The SELECT Phase 3b trial initiated with injectable semaglutide 2.4 mg investigating effects on cardiovascular
outcomes in people with overweight or obesity
Phase 1 trial initiated with PYY 1875 investigating safety, tolerability and pharmacokinetics of single doses as
monotherapy and in combination with semaglutide in subjects with overweight or obesity
Biopharma
•
•
•
GHD: Growth hormone deficiency
changing
diabetes®
Cardiovascular safety data added to SaxendaⓇ label in the USA
Successful completion of phase 3a extension trial with once-weekly somapacitan in adults with GHD
N8-GP submitted for regulatory approval in Japan
Successful completion of phase 2 trial explorer5 with concizumab to evaluate the efficacy and safety of
prophylactic administration in people with severe Haemophilia A without inhibitors
Novo Nordisk expands its growth disorders franchise with the acquisition of the North American rights to
Macrilen™, the first and only FDA approved product for diagnosis of growth hormone deficiency in adults
novo nordiskView entire presentation